Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17A | Q9UEE5 | 11/20 | 0.56 |
| ▸ | STK17B | O94768 | 6/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | AXL | P30530 | 1/20 | 0.46 |
| ▸ | ULK1 | O75385 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 2/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | INSR | P06213 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3448855 | 0.84 | STK17A (0.62) | STK17ASTK17BMAPK1AXL | |
| SCHEMBL3448261 | 0.84 | STK17A (0.59) | STK17ASTK17BMAPK1AXL | |
| SCHEMBL3344593 | 0.83 | STK17A (0.60) | STK17ASTK17BMAPK1AXLULK1 | |
| SCHEMBL3447158 | 0.82 | STK17A (0.62) | STK17ASTK17B | |
| SCHEMBL3450081 | 0.81 | STK17A (0.53) | STK17ASTK17BMAPK1AXLULK1 | |
| SCHEMBL3450582 | 0.81 | STK17A (0.59) | STK17ASTK17BAXLSYK | |
| Hydrochloric Acid SCHEMBL3451159 | 0.81 | STK17A (0.53) | STK17ASTK17BMAPK1AXLULK1 | |
| SCHEMBL13310336 | 0.80 | CSNK2A1 (0.55) | STK17ASTK17BIGF1RCDK1FGFR1 | |
| SCHEMBL3449490 | 0.80 | STK17A (0.57) | STK17ASTK17BAXL | |
| SCHEMBL3449788 | 0.80 | STK17A (0.57) | STK17ASTK17BMAPK1AXLULK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | STK17A 1984/4885STK17B 2457/4885MAPK1 2905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.